Monitor for closing announcement and any subsequent disclosure of purchase price and use of proceeds. The sale is part of a broader strategic restructuring alongside the Treeline merger and Mass Cytometry divestiture — watch for updates on those transactions as well.
Price Chart
Executive Summary
Standard BioTools announced a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days, subject to customary conditions. No financial terms were disclosed, and the filing does not include any financial results or guidance.
Key Facts
- Definitive agreement to sell Microfluidics business to ARCHIMED announced on October 5, 2026.
- Transaction expected to close in approximately 30 days, subject to customary closing conditions.
- No financial terms, purchase price, or valuation disclosed in the filing.
- The filing references ongoing related transactions: a proposed merger with Treeline Biosciences and sale of Mass Cytometry business to Element Biosystems.
Financial Impact
No financial terms disclosed; impact depends on undisclosed purchase price and use of proceeds.
Risk Factors
- Transaction may not close if customary conditions are not satisfied or waived.
- Termination of the agreement could require Standard BioTools to pay a termination fee.
- Competing offers or acquisition proposals could disrupt the sale.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-038624 |
| Document: ef20083295_ex99-1.htm | 0001140361-26-038624 |
| Document: 0001140361-26-038624-index-headers.html | 0001140361-26-038624 |
| Document: 0001140361-26-038624-index.html | 0001140361-26-038624 |
| Document: 0001140361-26-038624.txt | 0001140361-26-038624 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | EFFECT | $0.6400 $0.6056 | ▼ −5.38% | ▼ −4.85% | $0.6130 (−4.22%) |
Oct 21, 2026 6d ago | S-4/A | $0.6500 $0.6400 | ▲ +1.54% | ▲ +0.36% | $0.6130 (+5.69%) |
Oct 9, 2026 17d ago | S-4/A | $0.6578 $0.6589 | ▲ +0.17% | ▲ +0.18% | $0.6130 (−6.81%) |
Oct 5, 2026 21d ago | 425 | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.6130 (−15.10%) |
Oct 5, 2026 21d ago | 8-K | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.6130 (−15.10%) |
Oct 5, 2026 21d ago | Press Release | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.6130 (−15.10%) |
Sep 30, 2026 26d ago | 425 | $0.7283 $0.7447 | ▲ +2.25% | ▲ +1.51% | $0.6130 (−15.83%) |
Sep 30, 2026 26d ago | 8-K | $0.7283 $0.7447 | ▲ +2.25% | ▲ +1.51% | $0.6130 (−15.83%) |
Jul 29, 2026 12w ago | 425 | $0.8739 $0.8973 | ▲ +2.68% | ▲ +1.00% | $0.6130 (−29.85%) |
Jul 28, 2026 13w ago | Press Release | $0.7947 $0.8739 | ▲ +9.97% | ▲ +11.50% | $0.6130 (−22.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers